Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:ย  Laura J. Esserman, MD, Read More

2024-06-28T12:13:13-04:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Read More

2024-03-25T08:59:17-04:00November 1st, 2017|Endocrine, Evidence, MammaPrint, STO-3|
Go to Top